|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | |
| A61K 31/337 |
| (11) | Number of the document | 3083692 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14833308.1 |
| Date of filing the European patent application | 2014-12-17 | |
| (97) | Date of publication of the European application | 2016-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/070992 |
| Date | 2014-12-17 |
| (87) | Number | WO 2015/095418 |
| Date | 2015-06-25 |
| (30) | Number | Date | Country code |
| 201361917264 P | 2013-12-17 | US |
| (72) |
DENNIS, Mark S., US
EBENS, Allen, US
IRVING, Bryan, US
JUNTTILA, Teemu T., US
LI, Ji, US
|
| (73) |
F. Hoffmann-La Roche AG,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES |
| METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES |